Big ass IPO? Not really… ‘Shares soar as Atai Life Sciences IPO’s on the Nasdaq’ is the story being spun around Atai’s (ATAI.Q) first crack at going public last…
CYBN.NE
Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Cybin demonstrated their proof of concept for…
In the cannabis sector, there is a wide net of different types of companies from growers to extractors to logistics & tech and everything in-between. In the earlier days…
PTSD is fascinating in that two people can have identical experiences, one can largely forget the experience while the other is in for a lifetime of suffering. What…
Through the last year of the COVID-19 pandemic, healthcare workers have been on the front lines, bearing the brunt of the challenging circumstances. And, in an attempt to repay…
Cybin (CYBN.NE) announced they are sponsoring Kernel’s feasibility study of its Kernel Flow technology to measure Ketamine’s psychedelic effect on cerebral cortex hemodynamics. Cybin announced in January that they…
Cybin (CYBN.NE) announced they have filed an international patent application that brings the potential to obtain patent coverage in 153 countries. The application is governed by the Patent Cooperation…
They seem to have been born that way. They are naturally incapable of grasping and developing a manner of living which demands rigorous honesty. Today Alcoholics Anonymous (AA) is…
Cybin (CYBN.NE) announced that the Institutional Review Board (IRB) has granted them approval to begin the study of its sublingual psilocybin formulation, CYB001, in a Phase II clinical trial…